City of Hope Unveils AI and Cancer Breakthroughs at AACR
LOS ANGELES, April 16, 2026 City of Hope announced that its scientists will present groundbreaking research findings on cancer...
Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
LOS ANGELES, April 16, 2026 City of Hope announced that its scientists will present groundbreaking research findings on cancer...
Fort Myers, Florida | April 13, 2026 NeoGenomics, Inc. has announced the presentation of multiple scientific abstracts at the...
San Diego, USA & Suzhou, China, April 2, 2026 Strong Clinical Efficacy in MSS Colorectal Cancer In a major...
South San Francisco, California, USA, April 6, 2026 First-in-Class Epigenetic Therapy Enters Clinical Development In a major step forward...
Hong Kong, April 6, 2026 Promising Results in Immunotherapy-Resistant NSCLC In a significant advancement for lung cancer immunotherapy, Akeso,...
San Diego, USA & Suzhou, China, April 2, 2026 Breakthrough Collaboration in Immuno-Oncology In a significant step forward for...
HYDERABAD, India, Feb. 16, 2026 — The University of Hyderabad and MNJ Institute of Oncology & Regional Cancer Centre...
SYDNEY, Dec. 10, 2025 — Kazia Therapeutics Limited (NASDAQ: KZIA) unveiled compelling clinical and translational data highlighting the ability...
WILMINGTON, DE — November 21, 2025 — Telomir Pharmaceuticals announced new preclinical findings showing that its investigational compound Telomir-1...
Madrid, Spain – October 11, 2025 – AstraZeneca presented groundbreaking clinical trial results from four major Phase III studies...
